Literature DB >> 7713988

Antiproliferative activity of liposomal epirubicin on experimental human gliomas in vitro and in vivo after intratumoral/interstitial application.

D K Todorov1, S S Ninjo, W J Zeller.   

Abstract

Liposomal epirubicin was prepared using the controlled detergent dialysis method. The entrapment rate was 65.5 +/- 6.4%. The mean particle size was 210 +/- 38 nm. In vitro, a concentration-dependent antiproliferative activity of free epirubicin was observed. Liposome-entrapped epirubicin was superior to the free drug; the ID50 of the liposomal preparation was about 1.6-fold lower as compared to the free drug. Intratumoral/interstitial (i.t./i.s.) application of liposomal epirubicin was likewise superior to i.t./i.s. application of the free drug.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7713988     DOI： 10.1007/bf01198098

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  16 in total

1.  Intraneoplastic application of metrizamide-containing liposomes: kinetic studies with computed tomography.

Authors:  B Wowra; K Cremer; H Stricker; W J Zeller
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

Review 2.  The role of chemotherapy in the treatment of primary tumors of the central nervous system.

Authors:  T J Moynihan; S A Grossman
Journal:  Cancer Invest       Date:  1994       Impact factor: 2.176

3.  Incorporation of the antitumor alkaloid thaliblastine in liposomes enhances its cytotoxic activity in vitro.

Authors:  D K Todorov; G Deliconstantinos
Journal:  Experientia       Date:  1982-07-15

4.  Establishment and characterization of human glioblastoma cell lines in vitro and their xenografts in nude mice.

Authors:  H Fischer; W J Zeller; K Schwechheimer; K J Hutter; B Wowra; S Kunze; V Sturm
Journal:  Onkologie       Date:  1989-08

5.  Interstitial chemotherapy of experimental gliomas.

Authors:  W J Zeller; S Bauer; T Remmele; B Wowra; V Sturm; H Stricker
Journal:  Cancer Treat Rev       Date:  1990-09       Impact factor: 12.111

Review 6.  Pharmacokinetic determinants of the activity and toxicity of antitumour agents.

Authors:  D R Newell
Journal:  Cancer Surv       Date:  1989

Review 7.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 8.  Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential.

Authors:  G Gregoriadis; A T Florence
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

9.  Antiproliferative activity of the non-myelotoxic antitumour agent of plant origin, Thaliblastine, on two human glioma cell lines.

Authors:  D K Todorov; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 10.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546
View more
  3 in total

Review 1.  Topoisomerases as anticancer targets.

Authors:  Justine L Delgado; Chao-Ming Hsieh; Nei-Li Chan; Hiroshi Hiasa
Journal:  Biochem J       Date:  2018-01-23       Impact factor: 3.857

2.  Vitamin C-driven epirubicin loading into liposomes.

Authors:  Dominik Lipka; Jerzy Gubernator; Nina Filipczak; Sabine Barnert; Regine Süss; Mateusz Legut; Arkadiusz Kozubek
Journal:  Int J Nanomedicine       Date:  2013-09-23

3.  Efficient human breast cancer xenograft regression after a single treatment with a novel liposomal formulation of epirubicin prepared using the EDTA ion gradient method.

Authors:  Jerzy Gubernator; Dominik Lipka; Mariola Korycińska; Katarzyna Kempińska; Magdalena Milczarek; Joanna Wietrzyk; Rafał Hrynyk; Sabine Barnert; Regine Süss; Arkadiusz Kozubek
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.